News Story: Full Text
Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details
Braintumor Website

 

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Al's Comment:

This is one of the most important articles of the year.  It discusses the results of the first small ICT-107 vaccine trial.  The key outcome:  "At a median follow-up of 40.1 months, six of 16 newly diagnosed GBM patients showed no evidence of tumor recurrence. "

Notice the Acknowledgments section:  This study was supported by funding from Musella Foundation For Brain Tumor Research & Information, Inc. and ImmunoCellular Therapeutics Ltd.

This confirms that we (The Musella Foundation) seek out and fund the best research. Not only did we fund this project, but we also funded the early development on one of the targets of the vaccine.  This is a perfect example of how important YOUR donations are.  People always ask me if making donations can make a difference. This proves it.



Website: http://www.springerlink.com/content/n0018574g9m4v587/fulltext.html

Posted on: 08/29/2012

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Surasak PhuphanichContact Information, Christopher J. Wheeler4, 2 Contact Information, Jeremy D. Rudnick1, Mia Mazer2, HongQian Wang2, Miriam A. Nuño2, Jaime E. Richardson2, Xuemo Fan5, Jianfei Ji2, Ray M. Chu2, James G. Bender3, Elma S. Hawkins3, Chirag G. Patil2, Keith L. Black2 and John S. Yu3, 2

(1)  Neuro-Oncology Program, Department of Neurosurgery and Neurology, Cedars-Sinai Medical Center, 8631 W. 3rd Street Suite 410 E, Los Angeles, CA 90048, USA
(2)  Neuro-Oncology Program, Department of Neurosurgery, Cedars-Sinai Medical Center, 8631 W. 3rd Street Suite 800 E, Los Angeles, CA 90048, USA
(3)  ImmunoCellular Therapeutics Ltd., Woodland Hills, CA, USA
(4)  Department of Neurosurgery, Cedars-Sinai Medical Center, 110 N. George Burns Road, Davis 2097, Los Angeles, CA 90048, USA
(5)  Department of Pathology, Cedars-Sinai Medical Center, 8700 Beverly Blvd. room 8725, Los Angeles, CA 90048, USA

Contact Information Surasak Phuphanich (Corresponding author)
Email: phuphanich@cshs.org

Contact Information Christopher J. Wheeler (Corresponding author)
Email: wheelerc@cshs.org

Received: 1 March 2012  Accepted: 6 July 2012  Published online: 31 July 2012

Abstract
Background  
This study evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population (ICT-107).
Methods  
TAA epitopes included HER2, TRP-2, gp100, MAGE-1, IL13Rα2, and AIM-2. HLA-A1- and/or HLA-A2-positive patients with glioblastoma (GBM) were eligible. Mononuclear cells from leukapheresis were differentiated into dendritic cells, pulsed with TAA peptides, and administered intradermally three times at two-week intervals.
Results  
Twenty-one patients were enrolled with 17 newly diagnosed (ND-GBM) and three recurrent GBM patients and one brainstem glioma. Immune response data on 15 newly diagnosed patients showed 33 % responders. TAA expression by qRT-PCR from fresh-frozen tumor samples showed all patient tumors expressed at least three TAA, with 75 % expressing all six. Correlations of increased PFS and OS with quantitative expression of MAGE1 and AIM-2 were observed, and a trend for longer survival was observed with gp100 and HER2 antigens. Target antigens gp100, HER1, and IL13Rα2 were downregulated in recurrent tumors from 4 HLA-A2+ patients. A decrease in or absence of CD133 expression was seen in five patients who underwent a second resection. At a median follow-up of 40.1 months, six of 16 ND-GBM patients showed no evidence of tumor recurrence. Median PFS in newly diagnosed patients was 16.9 months, and median OS was 38.4 months.
Conclusions  
Expression of four ICT-107 targeted antigens in the pre-vaccine tumors correlated with prolonged overall survival and PFS in ND-GBM patients. The goal of targeting tumor antigens highly expressed on glioblastoma cancer stem cells is supported by the observation of decreased or absent CD133 expression in the recurrent areas of gadolinium-enhanced tumors.

Keywords  Dendritic cell immunotherapy – Cancer stem cells – Cancer vaccine – CTL – Epitopes – Glioblastoma

Surasak Phuphanich and Christopher J. Wheeler contributed equally to this study.
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740